Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing next-generation radiopharmaceuticals for cancer treatment. Utilizing their proprietary Fast-Clear™ linker technology, they create targeted alpha therapies that connect alpha-emitting isotopes to cancer-seeking molecules, allowing for precise delivery of cytotoxic agents to tumors. This innovative approach aims to improve patient outcomes by selectively killing cancer cells while minimizing damage to healthy tissues. As a spin-out from a leading radiopharmaceutical manufacturer, Fusion has a robust supply chain and is positioned to scale its production to meet global market needs, making it a promising player in the precision medicine landscape.
Something looks off?On-site & Remote